Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Plasma Protease C1-Inhibitor Market From 2025 to 2029?

In recent times, there has been a swift expansion in the market size of plasma protease c1-inhibitor. This market is projected to escalate from $3.37 billion in 2024 to $3.85 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.4%. The impressive growth during the historic phase is primarily due to the rising incidence of hereditary angioedema, heightened awareness concerning uncommon genetic conditions, growing demand for plasma-derived biologics, an upsurge in diagnostic rates for c1-inhibitor deficiency, and an increasing adoption of replacement therapy in emergency medical care.

There is a strong expectation for a swift expansion in the plasma protease c1-inhibitor market in the coming years, with predictions suggesting a rise to $6.53 billion by 2029, courtesy of a compound annual growth rate (CAGR) of 14.1%. This predicted growth in the forecast period comes as a result of an escalating concentration on personalized medicine, an uptick in pipeline developments for C1-inhibitor therapies under clinical trial, a burgeoning demand for preventative treatments, an increased availability of C1-inhibitor infusion therapies that can be administered at home, and a rising cognizance of C1-inhibitor deficiencies in surgical scenarios. Prominent trends for the forecast period comprise the creation of orphan drug applications, development of low-immunogenic variants, the embracing of genomic tools, incorporation into telemedicine platforms, and the drive towards innovative long-acting C1-inhibitors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24659&type=smp

What Elements Are Contributing To Growth In The Plasma Protease C1-Inhibitor Market?

Increased funding for rare diseases is set to spur the growth of the plasma protease C1-inhibitor market in the future. Defined as health conditions that afflict less than 1 in 2,000 people, rare diseases often involve ongoing, progressive symptoms that could be fatal or cause disability. Factors like the growing acknowledgment of unfulfilled medical needs and the potential for significant profit through beneficial regulatory mechanisms like orphan drug designation, market monopoly, and lowered development costs, primarily fuel this increased investment. Such funding supports the advancement of plasma protease C1-inhibitors by financing research and innovation aimed at treating hereditary angioedema and other rare conditions where a lack of C1-inhibitor causes severe symptoms, thereby hastening the introduction of targeted therapies. For example, Global Genes, a U.S. nonprofit organization, reported that in April 2024, those companies formulating drugs for rare diseases amassed $7.1 billion in the first quarter of 2024, a whopping 307% rise from the $1.8 billion pooled in the corresponding period in 2023. Hence, the escalating investment in rare diseases is fueling the growth of the plasma protease C1-inhibitor market.

Which Segments Are Detailed In The Global Plasma Protease C1-Inhibitor Market Report?

The plasma protease c1-inhibitor market covered in this report is segmented –

1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist

2) By Dosage Form: Lyphophlised, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor

2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor

3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor

4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor

5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist

Which Emerging Trends And Strategic Shifts Are Shaping The Plasma Protease C1-Inhibitor Market?

Prominent players in the plasma protease C1-inhibitor market are concentrating on product advancements, such as injectable prescription drugs, aiming to provide rapid, effective comfort for patients with hereditary angioedema and enhance treatment results. These medicines that are administered through injection help in replenishing or substituting plasma protease C1-inhibitor to control inflammation and thwart swelling episodes. For example, in December 2022, Takeda Pharmaceutical Company Limited, a pharmaceutical corporation based in Japan, introduced CINRYZE in India. CINRYZE is the initial injectable C1 esterase inhibitor confirmed by FDA for prophylactic therapy in individuals who are six years old or above. It proficiently diminishes the frequency, intensity, and span of hereditary angioedema (HAE) attacks by boosting plasma concentrations of C1-INH, effectively preventing overproduction of bradykinin and managing the related swelling.

Who Are The Key Contributors To Growth In The Plasma Protease C1-Inhibitor Market?

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V., Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, Lev Pharmaceuticals.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protease-c1-inhibitor-global-market-report

Which Region Is Projected To Lead The Plasma Protease C1-Inhibitor Market By 2025?

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24659&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model